Niga-ichigoside F1 is primarily studied for its potential anti-inflammatory and immunomodulatory effects. It has shown activity in inhibiting the production of pro-inflammatory cytokines, making it a candidate of interest in research related to autoimmune diseases and chronic inflammation. Additionally, it has demonstrated protective effects in liver injury models, suggesting possible applications in hepatoprotective therapies. Its bioactivity in cellular signaling pathways, particularly those involving NF-κB and MAPK, supports ongoing exploration for therapeutic use in inflammatory and oxidative stress-related conditions.